Immix Biopharma raises $10M via private placement; appoints new director

Immix Biopharma, Inc.

Gross proceeds of ~$10M from sale of 3.24M shares at $1.94/share and 1.91M pre-funded warrants at $1.9399.
Net proceeds of ~$9.55M; funds to be used for working capital and general corporate purposes.
Pre-funded warrants exercisable at $0.0001/share, no expiration, with 19.99% blocker provision.
Company to file resale registration statement within 30 days, seek effectiveness within 45 days.
Yekaterina Chudnovsky appointed to board as independent director effective August 22, 2023.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yekaterina Chudnovsky

Director

IMMX · Immix Biopharma, Inc.

Effective: 2023-08-22
Filed: August 22, 2023, 7:59 PM ET

Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yekaterina Chudnovsky was appointed as Director at Immix Biopharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into Securities Purchase Agreement with a certain accredited investor valued at approximately $10 million (effective 2023-08-21).

Action: entry
Agreement: equity purchase
Counterparty: a certain accredited investor
Value: approximately $10 million
Effective: 2023-08-21

Exact text from the filing

On August 21, 2023, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a certain accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement transaction (the “Private Placement”) (i) 3,241,076 shares (the “Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and (ii) pre-funded warrants to purchase 1,913,661 shares of Common Stock (the “Pre-Funded Warrants”).

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.